Semaglutide

A GLP‑1 receptor agonist with proven ASCVD benefit and strong weight loss is a great candidate drug for patients with cardiovascular disease and obesity. However, it is preferred for HFpEF and it has not been shown to reduce HFrEF hospitalization. It may be added later for weight or ASCVD risk, but it does not replace another cardioprotective drug for HF benefit as a first step.

  • Further Developments
End Session and View Feedback
  • Order a cappuccino and a kanelbulle anyway [undo]
  • Validate the emotion [undo]
  • A 70 years old male with hematuria [undo]
  • Χρησιμοποιώ μόνο Μεντελική πιθανότητα [undo]
  • Calcium: Increased; Potassium: Decreased; Sodium: Decreased [undo]
  • Semaglutide [undo]

Map: Michael Green_GEMD_2 (1116)
Node: 21124
Score:

reset

OpenLabyrinth
OpenLabyrinth is an open source educational pathway system

Review your pathway

  • Blame the patient for non-adherence
  • Order a cappuccino and a kanelbulle anyway
  • Validate the emotion
  • A 70 years old male with hematuria
  • Χρησιμοποιώ μόνο Μεντελική πιθανότητα
  • Calcium: Increased; Potassium: Decreased; Sodium: Decreased
  • Semaglutide

Reminder

empty_reminder_msg

FINISH

Time is up